dc.contributor.author | Masmudi-Martín, M | |
dc.contributor.author | Zhu, L | |
dc.contributor.author | Sanchez-Navarro, M | |
dc.contributor.author | Priego, N | |
dc.contributor.author | Casanova-Acebes, M | |
dc.contributor.author | Giralt, E | |
dc.contributor.author | Masmudi-Martín, M. | |
dc.contributor.author | Zhu, L. | |
dc.contributor.author | Sanchez-Navarro, M. | |
dc.contributor.author | Priego, N. | |
dc.contributor.author | Casanova-Acebes, M. | |
dc.contributor.author | Ruiz-Rodado, V | |
dc.contributor.author | Giralt, E. | |
dc.contributor.author | Valiente, Manuel | |
dc.date.accessioned | 2021-04-21T06:25:07Z | |
dc.date.available | 2021-04-21T06:25:07Z | |
dc.date.issued | 2021-02 | |
dc.identifier.citation | Adv Drug Deliv Rev.2021 Feb;169:79-99. | es_ES |
dc.identifier.issn | 0169-409X | es_ES |
dc.identifier.uri | http://hdl.handle.net/20.500.12105/12709 | |
dc.description.abstract | Brain metastasis is emerging as a unique entity in oncology based on its particular biology and, consequently, the pharmacological approaches that should be considered. We discuss the current state of modelling this specific progression of cancer and how these experimental models have been used to test multiple pharmacologic strategies over the years. In spite of pre-clinical evidences demonstrating brain metastasis vulnerabilities, many clinical trials have excluded patients with brain metastasis. Fortunately, this trend is getting to an end given the increasing importance of secondary brain tumors in the clinic and a better knowledge of the underlying biology. We discuss emerging trends and unsolved issues that will shape how we will study experimental brain metastasis in the years to come. | es_ES |
dc.description.sponsorship | The authors want to acknowledge the work of the many authors cited that have been used to write this review. Research in the Brain Metastasis Group is supported by MINECO (SAF2017-89643-R) (M.V.), Fundacio La Marato de TV3 (141) (M.V.), Melanoma Research Alliance (Bristol-Myers Squibb-Melanoma Research Alliance Young Investigator Award 2017 (498103)) (M.V.), Fundacion Ramon Areces (CIVP19S8163) (M.V.), Worldwide Cancer Research (19-0177) (M.V.), H2020-FETOPEN (828972) (M. V.), Cancer Research Institute (Clinic and Laboratory Integration Program CRI Award 2018 (54545)) (M.V.), AECC (Coordinated Translational Groups 2017 (GCTRA16015SEOA) (M.V.), LAB AECC 2019 (LABAE19002VALI) (M.V.)), ERC CoG (864759) (M.V.), AECC Postdoctoral Grant (POSTD19016PRIE) (N.P), La CaixaSevero Ochoa International PhD Program Fellowship (LCF/BQ/SO16/52270014) (L.Z.). M.V. is an EMBO YIP (4053). M.C-A is supported by the 2020 AACR-AstraZeneca Immuno-oncology Research Fellowship, Grant Number 20-40-12-CASA. CNIO is supported by the ISCIII, the Ministerio de Ciencia e Innovacion, and is a Severo Ochoa Center of Excellence (SEV-2015-0510). | es_ES |
dc.language.iso | eng | es_ES |
dc.type.hasVersion | SMUR | es_ES |
dc.rights.uri | http://creativecommons.org/licenses/by-nc-nd/4.0/ | * |
dc.subject | EXPERIMENTAL MODELS | es_ES |
dc.subject | PRECLINICAL THERAPY | es_ES |
dc.subject | BRAIN METASTASIS | es_ES |
dc.subject | ORGANOTROPISM | es_ES |
dc.subject | BBB | es_ES |
dc.subject | BTB | es_ES |
dc.subject | SMALL-MOLECULE DRUGS | es_ES |
dc.subject | NANOMEDICINES | es_ES |
dc.subject | IMMUNOTHERAPY | es_ES |
dc.title | Brain metastasis models: What should we aim to achieve better treatments? [preprint] | es_ES |
dc.type | preprint | es_ES |
dc.rights.license | Attribution-NonCommercial-NoDerivatives 4.0 Internacional | * |
dc.identifier.pubmedID | 33321154 | es_ES |
dc.format.volume | 169 | es_ES |
dc.format.page | 79-99 | es_ES |
dc.identifier.doi | 10.1016/j.addr.2020.12.002 | es_ES |
dc.contributor.funder | Ministerio de Economía y Competitividad (España) | |
dc.contributor.funder | Fundación La Marató TV3 | |
dc.contributor.funder | Bristol-Myers Squibb | |
dc.contributor.funder | Fundación Ramón Areces | |
dc.contributor.funder | Worldwide Cancer Research | |
dc.contributor.funder | Unión Europea. Comisión Europea. H2020 | |
dc.contributor.funder | Cancer Research Institute (Clinic and Laboratory Integration Program CRI Award 2018) | |
dc.contributor.funder | Asociación Española Contra el Cáncer | |
dc.contributor.funder | European Research Council | |
dc.contributor.funder | Fundación La Caixa | |
dc.contributor.funder | AstraZeneca | |
dc.contributor.funder | Instituto de Salud Carlos III | |
dc.contributor.funder | Ministerio de Ciencia e Innovación. Centro de Excelencia Severo Ochoa (España) | |
dc.description.peerreviewed | No | es_ES |
dc.identifier.e-issn | 1872-8294 | es_ES |
dc.relation.publisherversion | https://doi.org/10.1016/j.addr.2020.12.002. | es_ES |
dc.identifier.journal | Advanced drug delivery reviews | es_ES |
dc.repisalud.institucion | CNIO | es_ES |
dc.repisalud.orgCNIO | CNIO::Grupos de investigación::Grupo de Metástasis Cerebral | es_ES |
dc.relation.projectID | info:eu-repo/grantAgreement/ES/SAF2017-89643-R | es_ES |
dc.relation.projectID | info:eu-repo/grantAgreement/EC/H2020/828972 | es_ES |
dc.relation.projectID | info:eu-repo/grantAgreement/ES/141 | es_ES |
dc.relation.projectID | info:eu-repo/grantAgreement/ES/CIVP19S8163 | es_ES |
dc.relation.projectID | info:eu-repo/grantAgreement/ES/GCTRA16015SEOA | es_ES |
dc.relation.projectID | info:eu-repo/grantAgreement/ES/LABAE19002VALI | es_ES |
dc.relation.projectID | info:eu-repo/grantAgreement/EC/H2020/864759 | es_ES |
dc.relation.projectID | info:eu-repo/grantAgreement/ES/POSTD19016PRIE | es_ES |
dc.relation.projectID | info:eu-repo/grantAgreement/ES/LCF/BQ/SO16/52270014 | es_ES |
dc.relation.projectID | info:eu-repo/grantAgreement/EC/20-40-12-CASA | es_ES |
dc.relation.projectID | info:eu-repo/grantAgreement/ES/SEV-2015-0510 | es_ES |
dc.rights.accessRights | open access | es_ES |